Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma

Circulating tumor DNA (ctDNA) is assumed to reflect tumor burden and has been suggested as a tool for prognostication and follow‐up in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the prognostic value of ctDNA and its relation with tumor burden has yet to be substantia...

Descripción completa

Detalles Bibliográficos
Autores principales: Strijker, Marin, Soer, Eline C., de Pastena, Matteo, Creemers, Aafke, Balduzzi, Alberto, Beagan, Jamie J., Busch, Olivier R., van Delden, Otto M., Halfwerk, Hans, van Hooft, Jeanin E., van Lienden, Krijn P., Marchegiani, Giovanni, Meijer, Sybren L., van Noesel, Carel J., Reinten, Roy J., Roos, Eva, Schokker, Sandor, Verheij, Joanne, van de Vijver, Marc J., Waasdorp, Cynthia, Wilmink, Johanna W., Ylstra, Bauke, Besselink, Marc G., Bijlsma, Maarten F., Dijk, Frederike, van Laarhoven, Hanneke W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004068/
https://www.ncbi.nlm.nih.gov/pubmed/31340061
http://dx.doi.org/10.1002/ijc.32586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004068/
https://www.ncbi.nlm.nih.gov/pubmed/31340061
http://dx.doi.org/10.1002/ijc.32586

Ejemplares similares